Kane Biotech Inc (CVE:KNE) Director Marc Edwards acquired 100,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was acquired at an average cost of C$0.14 per share, for a total transaction of C$14,000.00. Following the acquisition, the director now owns 1,846,000 shares of the company’s stock, valued at approximately C$258,440.

KNE opened at C$0.14 on Thursday. The company has a debt-to-equity ratio of 187.91, a quick ratio of 0.12 and a current ratio of 0.24. The stock has a market capitalization of $11.22 million and a P/E ratio of -3.68. The business has a 50 day simple moving average of C$0.13. Kane Biotech Inc has a 12-month low of C$0.06 and a 12-month high of C$0.15.

Kane Biotech (CVE:KNE) last posted its quarterly earnings data on Wednesday, May 22nd. The company reported C($0.01) earnings per share (EPS) for the quarter. The company had revenue of C$0.62 million for the quarter.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoo for dogs, cats, and horses under the Alosera trademark.

Further Reading: Why are gap-down stocks important?

Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.